Eli Lilly & Co.'s efforts to take on rivals Pfizer Inc. and Novartis AG in the lucrative cyclin-dependent kinase (CDK) 4/6 inhibitor space for advanced breast cancer have gotten another positive boost.
The company announced positive preliminary efficacy data from an interim analysis of the MONARCH 3 trial, showing a statistically significant...



![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

